cps 2

Drug Profile

cps 2

Alternative Names: rA2cp248/404-1030 Delta SH genetically stabilised; Recombinant live-attenuated respiratory syncytial virus vaccine - Medimmune/NIAID; Respiratory syncytial virus vaccine cps2; RSV vaccine live-attenuated genetically stabilised - Medimmune/NIAID

Latest Information Update: 25 Oct 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institute of Allergy and Infectious Diseases
  • Class Attenuated vaccines; Respiratory syncytial virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Respiratory syncytial virus infections

Most Recent Events

  • 01 Sep 2013 Phase-I clinical trials in Respiratory syncytial virus infections (prevention in infants) in USA (Intranasal)
  • 01 Sep 2013 National Institute of Allergy and Infectious Diseases initiates enrolment in a phase I trial for Respiratory syncytial virus infections (prevention) in USA (NCT01968083)
  • 01 Jan 2012 Preclinical trials in Respiratory syncytial virus infections in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top